Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central
Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial
stiffness in elderly patients with an elevated systolic blood pressure (SBP) and widened
pulse pressure (PP).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Amlodipine Hydrochlorothiazide LCZ 696 Olmesartan Olmesartan Medoxomil Sacubitril and valsartan sodium hydrate drug combination Valsartan